盐酸贝凡洛尔片对男性高血压患者勃起功能障碍的影响：一项多中心、前瞻性、单臂、开放的真实世界研究

The effect of bevantolol hydrochloride tablets on erectile dysfunction in male hypertensive patients: a multicenter, prospective, single-arm, open-label, real-world study

    摘要
  • 摘要:
    目的 评估真实世界中盐酸贝凡洛尔片对男性轻、中度高血压患者勃起功能障碍（ED）的影响。
    方法 收集2022年7月至2024年9月就诊于11家中心医院的男性轻、中度高血压患者，观察使用盐酸贝凡洛尔片12周前后患者的国际勃起功能指数（IIEF-5）评分与ED比例，以及使用盐酸贝凡洛尔片4、8、12周时的血压和心率变化。
    结果  最终纳入患者189例，与治疗前比较，使用盐酸贝凡洛尔片治疗12周后患者的IIEF-5评分中位数（P25, P75）从20（17，23）分增加到20（18，23）分（Z = –3.153，P = 0.002）；ED比例从66.14%（125/189）降至58.73%（111/189）（Z = 6.500，P = 0.011）；收缩压中位数（P25, P75）从142（136，150）mmHg降低至130（125，136）mmHg（P＜0.001），舒张压中位数（P25, P75）从90（86，98）mmHg降低至82（80，86）mmHg（P＜0.001），心率中位数（P25, P75）从81（78，88）次/min降至77（72，80）次/min（P＜0.001）。研究期间，未观察到盐酸贝凡洛尔片相关的不良心血管事件。
    结论 盐酸贝凡洛尔片能够减少男性轻、中度高血压患者的ED，同时能够平稳有效降低血压、心率，无明显不良反应，尤其适用于快心率的青年男性高血压患者。

     

    Abstract:
    Objective To evaluate the effect of bevantolol hydrochloride tablets on erectile dysfunction (ED) in mild to moderate male hypertensive patients in the real-world setting.
    Methods Mild to moderate male hypertensive patients who visited 11 central hospitals from July 2022 to September 2024 were collected. The scores of the International Index of Erectile Function (IIEF-5) and the proportion of ED before and 12 weeks after treatment with bevantolol hydrochloride tablets, as well as the changes in blood pressure, heart rate, and the decrease in blood pressure at 4, 8, and 12 weeks after treatment were observed.
    Results Finally, 189 patients were included. Compared with before treatment, after 12 weeks of treatment, the median (P25, P75) of IIEF-5 score of the patients increased from 20 (17, 23) points to 20 (18, 23) points (Z = –3.153, P = 0.002); the proportion of ED decreased from 66.14% (125/189) to 58.73% (111/189) (Z = 6.500, P = 0.011); The median (P25, P75) of systolic blood pressure decreased from 142 (136, 150) mmHg to 130 (125, 136) mmHg (P＜0.001), the median (P25, P75) of diastolic blood pressure decreased from 90 (86, 98) mmHg to 82 (80, 86) mmHg (P＜0.001), and the median (P25, P75) of heart rate decreased from 81 (78, 88) beats/min to 77 (72, 80) beats/min (P＜0.001). During the treatment, no cardiovascular events related to bevantolol hydrochloride tablets were observed.
    Conclusion Bevantolol hydrochloride tablets can reduce ED in mild to moderate male hypertensive patients, and can stably and effectively reduce blood pressure and heart rate without obvious adverse reactions, especially for young male hypertensive patients with a fast heart rate.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回